Moreover, studies have demonstrated that the absence of Col1 homotrimers significantly inhibits tumor growth and progression, while reshaping the tumor microbiome to enhance T cell infiltration and activation, thereby improving the efficacy of anti-PD-1 immunotherapy, providing robust evidence for the feasibility of COL1A1 as a potential therapeutic target (53). This evidence concerns the gene COL1A1 and neoplasm.